SCHEMBL7562860

SCHEMBL7562860

O=C(NCc1ccccc1F)C1CCC(Cc2nc3ncccc3[nH]2)CC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.48
RXFP1 Q9HBX9 1/20 0.48
KDM4E B2RXH2 3/20 0.46
LMNA P02545 2/20 0.45
PKM P14618 1/20 0.44
NPC1 O15118 1/20 0.43
TP53 P04637 1/20 0.43
HPGD P15428 1/20 0.43
RAB9A P51151 1/20 0.43
BACE1 P56817 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
HSD17B10 Q99714 1/20 0.43
KMT2A Q03164 1/20 0.43
MAPT P10636 3/20 0.42
POLB P06746 1/20 0.42
P2RX7 Q99572 1/20 0.41
MAPK1 P28482 1/20 0.41
GRM7 Q14831 1/20 0.41
CNR2 P34972 1/20 0.41
AR P10275 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7562851 1.00 ALDH1A1 (0.48) ALDH1A1RXFP1KDM4ELMNAPKM
SCHEMBL7085312 0.86 MAPK1 (0.53) ALDH1A1RXFP1KDM4ELMNAPKM
SCHEMBL7085306 0.86 MAPK1 (0.53) ALDH1A1RXFP1KDM4ELMNAPKM
SCHEMBL7088260 0.86 MAPK1 (0.53) ALDH1A1RXFP1KDM4ELMNAPKM
SCHEMBL7541212 0.79 PARP2 (0.47) ALDH1A1RXFP1KDM4ELMNAPKM
SCHEMBL7677632 0.79 PARP2 (0.47) ALDH1A1RXFP1KDM4ELMNAPKM
SCHEMBL7564217 0.78 PDE5A (0.44) KMT2A
SCHEMBL7695627 0.76 IDO1 (0.48) KDM4ELMNANPC1RAB9ASMN1; SMN2
SCHEMBL7695624 0.76 IDO1 (0.48) KDM4ELMNANPC1RAB9ASMN1; SMN2
SCHEMBL7692414 0.76 POLB (0.54) LMNANPC1RAB9ASMN1; SMN2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6495561-B2 TREATING MIGRAINE, DEPRESSION, ANXIETY, SCHIZOPHRENIA, PARKINSON'S DISEASE, OR STROKE MERCK & CO., INC. 2002-12-17 US disclosed
US-20020055519-A1 2-cyclohexyl imidazopyridine NMDA/NR2B antagonists MERCK SHARP & DOHME CORP. 2002-05-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020055519-A1 2-cyclohexyl imidazopyridine NMDA/NR2B antagonists GRIN2C, GRIN1, GRIN3A ALDH1A1 2175/4885RXFP1 2402/4885KDM4E 1232/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.